Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML (Q57219807)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22743624%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

title

Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22743624%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

0 references

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22743624%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Valérie Bardet

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22743624%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Eric Solary

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22743624%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Michaela Fontenay

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22743624%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

author name string

S Ettou

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22743624%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

C Humbrecht

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22743624%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

B Benet

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22743624%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

H Jammes

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22743624%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

T Clozel

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22743624%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

C Lacombe

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22743624%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

F Dreyfus

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22743624%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

P Mayeux

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22743624%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

publication date

5 June 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22743624%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22743624%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22743624%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22743624%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

page(s)

2297-2299

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22743624%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2012.152

6 February 2020

exact match

0 references

cites work

Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.152

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.152

MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.152

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.152

Hypermethylation of the gene promoter and enhancer region can regulate Fas expression and sensitivity in colon carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.152

Downregulation of Fas gene expression in Sézary syndrome is associated with promoter hypermethylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.152

5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.152

Rescue of early-stage myelodysplastic syndrome-deriving erythroid precursors by the ectopic expression of a dominant-negative form of FADD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.152

An elaborate pathway required for Ras-mediated epigenetic silencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.152

Epigenetic dysregulation of the DAP kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in acute leukaemias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.152

Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.152

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.152

DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.152

Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.152

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.152

21 January 2018

Identifiers

DOI

10.1038/LEU.2012.152

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22743624%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference